
    
      This is a single-center, randomized, double-blind, placebo-controlled, single ascending dose
      trial with single oral doses of HTI-2088 tablets to subjects at 3 levels (2.5, 3.75, 5 mg).
      Ten subjects will be enrolled at each dose level, randomized within groups at an active:
      placebo ratio of 4:1.
    
  